Investing.com -- There have been various big-name movers this week based on a range of different factors. While we can't cover them all in this article, here are Investing.com's stocks of the week:
Disney (NYSE:DIS)
While Disney shares have been on the rise for most of November so far, the stock made a strong 6.2% jump on Thursday after the company reported its latest quarterly earnings, with investors reacting positively to its streaming growth and outlook.
At the time of writing (12:40 pm ET) on Friday, Disney shares are trading above the $113 mark.
Reacting to its earnings release, analysts at Morgan Stanley (NYSE:MS) raised their target for the stock to $125 from $110, maintaining an Overweight rating.
"New guidance for multi-year growth reflects the expected returns from 1) a content turnaround and 2) ramping experiential investments," said the investment bank. "If it delivers, shares can again provide investors consistent double-digit adj. EPS growth as it builds, revitalizes, and monetizes its iconic brands & franchises."
MicroStrategy
MicroStrategy is another name that made substantial gains this week, rising more than 25% on Monday.
The stock surge came after the company revealed it had increased its Bitcoin holdings, acquiring approximately 27,200 bitcoins for around $2.03 billion in cash at an average price of approximately $74,463 per bitcoin, inclusive of fees and expenses.
The move increases the company's overall exposure to the BTC at a time of improving market sentiment based on hopes of favorable regulations and policies supporting the industry.
MicroStrategy's share price was boosted by the fact that Bitcoin surged to new all-time highs this week, peaking above $93,000 on Wednesday. On Friday, Bitcoin is trading at around $89,500.
Vaccine Stocks
Shares of major vaccine makers, including Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA), declined sharply on Friday after President-elect Donald Trump selected Robert F. Kennedy Jr. as his nominee for Secretary of Health and Human Services (HHS).
The announcement prompted a sell-off in vaccine stocks, with Pfizer falling over 4% and Moderna declining by over 6%. Meanwhile, the broader SPDR S&P Biotech ETF also dropped over 4%, while London-listed GSK and AstraZeneca (NASDAQ:AZN) both fell by over 3%.
Investors reacted based on concerns about the future of public health policy, given Kennedy's history of promoting vaccine skepticism and criticizing the U.S. Food and Drug Administration (FDA). Kennedy has been a vocal critic of vaccines and has pledged to overhaul the FDA.